Molecularly targeted cancer imaging is critical for fundamental improvements in cancer patient care, and image quality and diagnostic accuracy rely heavily on the affinity/specificity between the targeted receptor and targeting ligand (small molecules, peptides and antibodies). A heterodimeric ligand that simultaneously associates two linked ligands with two different targeting receptors provides a broadly applicable approach to convert low affinity ligands (Kdaffinity ~ mM - M) to the one with high avidity/specificity (Kdavidity ~ nM). Such high avidity heterodimers are usually pursued by: 1) synthesizing a number of heterodimers with different linkers; and 2) measuring their in vitro avidities individually. However, once the receptor of interest changes, repeating the entire procedure (including new heterodimer library synthesis and avidity measurement) is required for linker optimization. Even more disappointing is the fact that even by prudently selecting dual-receptor pairs where a potent heterodimer may be applied to a variety of tumors, in a particular lab using particular cell lines(s) where receptor distance(s) varied significantly, heterodimer library synthesis and avidity measurements needs to be conducted again. Therefore, the lack of a generic and rapid linker optimization platform has been considered as one of the major barriers for the widespread and routine utilization of heterodimeric ligand for preclinical and/or clinical studies. In order to overcome this problem, utilizing two bioorthogonal ligations, we propose the first, high-throughput, in vitro screening platform for easy preparation of high avidity heterodimers, which can be broadly applied to various dual-receptor combinations and different tumors. Such widespread applicable technology will significantly accelerate and/or enhance receptor-targeted cancer imaging using heterodimers, particularly in the following situations: 1) when targeted receptor(s) are expressed in low abundance; and 2) situations where no high affinity (and/or specificity) monovalent ligands are available.

Public Health Relevance

With the success and the influx of targeted cancer imaging and therapy, the development of high affinity/specificity targeting probe is extremely desirable. Heterodimeric ligand that simultaneously associates two linked ligands with two different biomarkers provides a broadly applicable approach to convert the low affinity ligands to the one with high avidity/specificity. Although there has been a considerable effort in the development of heterodimeric ligands, optimization of linkers for bivalency still remains as one major unresolved issue since it has been widely observed that the linker dramatically affects the avidity of bivalency. Therefore, utilizing two bioorthogonal ligations, we propose the first, high-throughput, in vitro screening platform for easy preparation of high avidity heterodimers, which can be broadly applied to various dual- receptor combinations and different tumors. Such widespread applicable technology can significantly accelerate and/or enhance receptor-targeted cancer imaging using heterodimers, particularly in the following situations: 1) targeted receptor(s) which are expressed in low abundance; and 2) situations where no high affinity (and/or specificity) monovalent ligands are available. In this proposal, two peptide ligands, targeting uPAR and Plectin-1 biomarkers respectively, are selected to pursue the corresponding high avidity heterodimer used for PET imaging of pancreatic cancer at early stage.

Agency
National Institute of Health (NIH)
Institute
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21EB020737-02
Application #
9134747
Study Section
Clinical Molecular Imaging and Probe Development (CMIP)
Program Officer
Conroy, Richard
Project Start
2015-09-30
Project End
2017-08-31
Budget Start
2016-09-01
Budget End
2017-08-31
Support Year
2
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Gai, Yongkang; Sun, Lingyi; Lan, Xiaoli et al. (2018) Synthesis and Evaluation of New Bifunctional Chelators with Phosphonic Acid Arms for Gallium-68 Based PET Imaging in Melanoma. Bioconjug Chem 29:3483-3494
Sun, Jingjing; Sun, Lingyi; Li, Jianchun et al. (2018) A multi-functional polymeric carrier for simultaneous positron emission tomography imaging and combination therapy. Acta Biomater 75:312-322
Ehlerding, Emily B; Sun, Lingyi; Lan, Xiaoli et al. (2018) Dual-Targeted Molecular Imaging of Cancer. J Nucl Med 59:390-395
Sun, Lingyi; Ding, Jiule; Xing, Wei et al. (2016) Novel Strategy for Preparing Dual-Modality Optical/PET Imaging Probes via Photo-Click Chemistry. Bioconjug Chem 27:1200-4
Gai, Yongkang; Xiang, Guangya; Ma, Xiang et al. (2016) Universal Molecular Scaffold for Facile Construction of Multivalent and Multimodal Imaging Probes. Bioconjug Chem 27:515-20